The third session of the 2024 #MWMsymposium will address methodological approaches to measuring #SDoH .
Featuring speakers from Northwestern Feinberg School of Medicine, Cleveland Clinic Lerner Research Institute, and RTI International.
Learn more: ow.ly/xUmW50RRoBY
Thank you Antoinette Davey Tim Pickles Joanne Greenhalgh 💙 and OutcomesFacilitator (PROMs) for sharing reflections of a great day looking at #PROMs across the life span with our members who had been unable to attend. Bringing the ISOQOL UK & Ireland PROMs SIG and the National PROMs Network together.
Excellent current state of play overview presentation today ISOQOL #ISOQOL23 from QUOKKA principal Investigator nance devlin on valuation of child health related quality of life for the EQ-5DY-3L and EQ-5DY-5L QUOKKA Research Program
Presenting the results of the qualitative research on content validity for a new patient reported outcome measure for Rheumatoid Arthritis Disease Activity at the ever wonderful #ISOQOL conference in Calgary
ISOQOL
CTRCardiffUni
Health and Care Research Wales
Congratulations to Elizabeth Unni on your appointment to Co-EiC JPatientRepOutcomes ! Excited to see her influence on the journal! ISOQOL
1/2 At ISOQOL Calgary today, QUOKKA's Diana Khanna presented her work 'Understanding the child's perception of HRQoL: a mixed methods approach' with Julie Ratcliffe
🌟 Talk by Kelly de Ligt about the ePRO implementation at the The Netherlands Cancer Institute
ISOQOL #ISOQOL
The #UKPROMs conference may be over, but we invite @ScHARRSheffield ISOQOL Welsh Value in Health Centre @Cedar_Cardiff NIHR Yorkshire & Humber ARC members to join our own National PROMs Network members in reflecting on a great day and what we learned.
📩co-ordinators at promsnetwork.co.uk
We are pleased to share about the ISOQOL annual meeting in Calgary, Canada, between October 18–21, 2023. Join us in Calgary for this meeting and check out a few presentations to be delivered by members and collaborators of the Person-centered Methods and Analytics Lab Tolu Sajobi
Reliance on clinician assessment of symptomatic toxicities can lead to an underestimation of patients’ experiences.
FDA Oncology draft guidance is a step forward , but more clarification on patient-reported tolerability is needed. Devin Peipert ISOQOL
pubmed.ncbi.nlm.nih.gov/37217665/